innerbuddies gut microbiome testing

Gut Microbiome & SIBO: How Bacterial Imbalance Affects Your Small Intestine

Small intestinal bacterial overgrowth (SIBO) often begins with a shift in the gut microbiome—especially in the small intestine, where the bacterial population is normally kept relatively low. When this balance tilts, bacteria that should be more limited in number can multiply in the small bowel, interfering with digestion and fermenting carbohydrates that would otherwise be absorbed in the upper gut.

That microbial “overcrowding” can set off a chain reaction. As bacterial populations change, they can increase gas production, disrupt normal nutrient breakdown, and impair the gut lining’s function. Over time, this can worsen symptoms like bloating, abdominal discomfort, diarrhea or constipation, and that full, heavy feeling after meals—symptoms many people also associate with broader digestive dysbiosis.

The good news: SIBO is closely linked to identifiable drivers of microbiome imbalance, such as altered gut motility, changes in stomach acid, certain medications, and underlying digestive conditions. By understanding how these factors influence the small-intestinal microbial environment—and which bacterial shifts tend to fuel fermentation and inflammation—you can better target the root causes and support restoration of a healthier, calmer small intestine.

Take the Gut Microbiome Test for SIBO Insights Test Your Gut Microbiome for SIBO
innerbuddies gut microbiome testing

Korte samenvatting

Small intestinal bacterial overgrowth (SIBO)

SIBO, or small intestinal bacterial overgrowth, occurs when an abnormally high and often mislocated bacterial population colonizes the small intestine due to weakened protective defenses such as stomach acid and migrating motor patterns. This dysbiosis leads to post-meal fermentation of incompletely digested carbohydrates, causing bloating, gas, abdominal pain, and changes in bowel habits (diarrhea, constipation, or irregularity), with potential malabsorption and nutrient deficiencies over time. Prevalence in the general population is modest (roughly 4–7%), but higher among people with motility- or structure-related risk factors, IBS patients with bloating, and other GI conditions, underscoring its clinical relevance as a contributor to gut symptoms.

Mechanistically, SIBO reflects a loss of the small intestine’s low-bacteria barrier and impaired clearance, driven by factors such as hypochlorhydria, reduced antimicrobial defenses, and disrupted migrating motor complexes. This allows colon-associated microbes to migrate upward and alter fermentation toward hydrogen and methane production, intensifying postprandial symptoms. The microbial pattern often includes reduced beneficial taxa (e.g., Faecalibacterium prausnitzii, Bifidobacterium) and elevated enteric and methane-producing taxa (e.g., Enterobacteriaceae, Methanobrevibacter), with functional activity centered on carbohydrate fermentation and short-chain fatty acid production. These changes can promote mucosal irritation, immune activation, and nutrient malabsorption.

Testing helps determine whether symptoms reflect true SIBO-related dysbiosis versus other conditions with similar presentations (IBS, celiac disease, medication-related malabsorption). By identifying hydrogen- vs. methane-producing communities and drivers of dysbiosis (motility, bile acid handling, gastric acidity), clinicians can tailor targeted strategies to reduce overgrowth and address root causes to reduce recurrence risk. InnerBuddies offers a personalized microbiome snapshot to guide interpretation of these patterns, monitor recovery after treatment, and support long-term prevention by tracking shifts toward a healthier ecosystem and aligning dietary and therapeutic steps with the patient’s microbial and metabolic signatures.

Take the Gut Microbiome Test for SIBO Insights Test Your Gut Microbiome for SIBO
innerbuddies gut microbiome testing

Belangrijkste inzichten

  1. Reduced levels of beneficial taxa (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale group, Akkermansia muciniphila, Bifidobacterium, Bacteroides fragilis group) weaken barrier integrity and permit small-intestine overgrowth by normally colonic microbes.
  2. Overgrowth of hydrogen-producing taxa such as Enterobacteriaceae (Escherichia/Shigella), oral-type Streptococcus, and Enterococcus drives excess gas and postprandial bloating.
  3. Methanogenic archaea like Methanobrevibacter smithii increase methane production, which is often linked to slower transit and constipation-predominant SIBO.
  4. Colon-associated Bacteroides spp. and Ruminococcus gnavus group can migrate into the small intestine, altering fermentation patterns and gas production.
  5. Dysbiosis favors fermentation pathways, amplifying gas and short-chain fatty acid byproducts after meals and increasing recurrence risk unless root causes (motility, acid, structural factors) are addressed.
innerbuddies gut microbiome testing

Overzicht van de aandoening

Functional bowel / related GI topics - Small intestinal bacterial overgrowth (SIBO)

Small intestinal bacterial overgrowth (SIBO) occurs when an abnormally high number of bacteria—often the “wrong” types or in the wrong location—build up in the small intestine. Normally, the small intestine has relatively low bacterial counts compared with the colon, helped by protective defenses like stomach acid and migrating gut motility patterns. When those safeguards weaken (for example, due to slow intestinal transit, structural changes, or impaired motility), microbes can proliferate and ferment carbohydrates that aren’t fully digested, contributing to bloating, gas, abdominal discomfort, diarrhea, and sometimes constipation.

A key driver of SIBO is gut microbiome imbalance across the gut–brain–immune axis. Dysbiosis can alter carbohydrate fermentation patterns, reduce beneficial microbial functions (such as those that support healthy barrier integrity), and promote conditions where gas-producing or opportunistic bacteria gain an advantage. In SIBO, bacterial metabolism may shift toward producing excess hydrogen, methane, or other fermentation byproducts—often worsening symptoms after meals. Over time, this altered microbial activity can also irritate the small intestinal lining, disrupt digestion and nutrient absorption, and contribute to deficiencies (e.g., B12 in some cases), especially when inflammation and malabsorption persist.

Understanding the bacterial changes linked to SIBO can help guide targeted strategies to restore balance. While the specific microbiology varies by person, common patterns include overrepresentation of bacteria associated with fermentation and altered community structure compared with the expected small-intestinal environment. Clinically, breath testing may reveal hydrogen and/or methane overgrowth, while symptom patterns and stool or nutritional clues can suggest the predominant functional shift. Because underlying causes (like motility issues, autoimmune or inflammatory conditions, past GI surgery, or chronic reflux/acid suppression) strongly influence recurrence risk, successful management typically focuses not only on reducing overgrowth but also on addressing the root factors that allow microbiome imbalance to re-establish.

Take the Gut Microbiome Test for SIBO Insights Test Your Gut Microbiome for SIBO
innerbuddies gut microbiome testing

Veelvoorkomende symptomen

  • Bloating and abdominal distension
  • Excess gas and flatulence
  • Abdominal pain or cramping (often after meals)
  • Diarrhea or frequent loose stools
  • Constipation or irregular bowel movements
  • Nausea and reduced appetite
  • Malabsorption symptoms (e.g., weight loss or nutrient deficiencies)
innerbuddies gut microbiome testing

Voor wie is dit relevant?

SIBO is especially relevant for people who experience persistent, meal-triggered bloating, gas, abdominal discomfort, and changes in stool patterns—particularly when symptoms suggest fermentation occurring in the small intestine rather than the colon. This can include those with diarrhea or frequent loose stools, constipation or irregular bowel movements, and cramping or abdominal pain that tends to worsen after eating. If symptoms have been recurring and don’t clearly match typical food intolerance alone, SIBO may be worth considering.

It may also be relevant for individuals who have risk factors that weaken normal small-intestinal defenses, such as slow intestinal transit, impaired gut motility, structural GI changes, or conditions that affect the gut–brain–immune signaling. People who have a history of GI surgery, chronic reflux or long-term acid suppression, or other motility-related disorders may be more prone to bacterial overgrowth migrating or flourishing where they shouldn’t. When gut microbiome balance is disrupted, the microbial community can shift toward producing excess hydrogen and/or methane, aligning with bloating and altered bowel habits.

SIBO is further relevant for those who show clues of malabsorption or nutritional disruption, such as unexplained weight loss or nutrient deficiencies (for example, low B12 in some cases), persistent nausea, or reduced appetite. Over time, ongoing fermentation by an overabundant or “misplaced” microbial community can irritate the small-intestinal lining and interfere with digestion and absorption. If breath testing or clinical evaluation suggests hydrogen- or methane-predominant patterns, SIBO may be particularly relevant for guiding treatment that not only targets overgrowth but also addresses underlying motility or immune-related drivers to reduce recurrence.

innerbuddies gut microbiome testing

Prevalentie – samenvatting

Small intestinal bacterial overgrowth (SIBO) is relatively common, but reported prevalence varies widely by study design, diagnostic method (especially breath testing vs. aspirate culture), and patient population. In the general adult population, estimates are often in the low single digits; a commonly cited range is roughly ~4–7% of people overall, with higher rates found when testing is performed using symptom-driven referrals.

Prevalence is notably higher in people with underlying risk factors that impair small-bowel motility or alter the gut environment. This includes conditions such as diabetes (especially with autonomic neuropathy), scleroderma, chronic constipation/slow transit, inflammatory bowel disease, prior abdominal surgery, and disorders associated with structural or functional changes in the small intestine. In these groups, studies commonly report prevalence that can rise to ~10–30% (and sometimes higher), largely because weakened migrating motor complex activity allows bacteria to proliferate in the small intestine.

SIBO is also frequently identified in subsets of patients who present with chronic gastrointestinal symptoms that overlap with other functional bowel disorders. For example, among individuals with irritable bowel syndrome (IBS), particularly those with prominent bloating, gas, and diarrhea or constipation, breath-test–positive SIBO has been reported around ~25–40% in some analyses. This higher prevalence aligns with the symptom pattern described for SIBO—post-meal bloating, excess gas, abdominal discomfort, and altered stool frequency—suggesting that in real-world clinical settings, SIBO is a meaningful, though not always the primary, contributor to microbiome-related GI complaints.

innerbuddies gut microbiome testing

Gut Microbiome & SIBO: How Bacterial Imbalance Affects Your Small Intestine

Small intestinal bacterial overgrowth (SIBO) is strongly linked to gut microbiome imbalance, particularly a disruption in how the small intestine maintains low bacterial density compared with the colon. When protective mechanisms—such as adequate stomach acid and regular migrating gut motility—are weakened, bacteria from other regions can proliferate or shift into the wrong location. This altered microbial distribution changes fermentation patterns, increasing gas production from carbohydrates that escape complete digestion.

In SIBO, the gut microbiome often shifts toward communities that metabolize available substrates more aggressively, which can lead to excess hydrogen and/or methane byproducts. These fermentation outputs can worsen symptoms like post-meal bloating, abdominal distension, cramping, and flatulence. Many people notice symptoms intensify after eating because nutrient availability directly fuels microbial activity in the small intestine, amplifying both gas generation and intestinal irritation.

Over time, microbiome-driven fermentation and inflammation may contribute to impaired digestion and nutrient absorption, which helps explain malabsorption-related symptoms such as weight loss or nutrient deficiencies (including possible vitamin B12 issues in some cases). The resulting dysregulation within the gut–brain–immune axis can further perpetuate diarrhea or constipation and may reduce appetite or promote nausea. Since recurrence risk is influenced by underlying drivers of dysbiosis—like slow transit, motility disorders, structural gut changes, or acid suppression—restoring a healthy microbiome typically requires addressing these root factors alongside targeting overgrowth.

Take the Gut Microbiome Test for SIBO Insights Test Your Gut Microbiome for SIBO
innerbuddies gut microbiome testing

Betrokken mechanismen

  • Loss of the small-intestine “low-bacteria” barrier: reduced stomach acid (hypochlorhydria), impaired antimicrobial peptide activity, and disrupted bile/enzymatic defense allow colon-like microbes to migrate and overgrow in the small bowel.
  • Impaired migrating motor complex (MMC) / gut motility: slow transit or motility disorders reduce clearance of luminal bacteria after meals, increasing bacterial residence time and promoting biofilm formation.
  • Microbiome dysbiosis that favors fermentation in the wrong location: shifts in community composition increase the number of taxa capable of fermenting carbohydrates that reach the small intestine, driving excess gas production (hydrogen and/or methane).
  • Post-meal substrate-driven microbial overactivity: meal intake increases available carbohydrates (and altered bile acids), directly fueling microbial fermentation and worsening postprandial bloating, distension, and cramping.
  • Gas-induced mucosal and neuromuscular irritation: hydrogen/methane and fermentation byproducts can increase luminal osmotic load, alter epithelial barrier function, and stimulate visceral hypersensitivity and intestinal motility changes that perpetuate symptoms.
  • Inflammation and impaired nutrient absorption/malabsorption: chronic dysbiosis-related inflammation and altered microbial metabolites can reduce brush-border function and nutrient uptake, contributing to deficiencies (including potential vitamin B12 issues) and weight loss.
  • Disruption of gut–brain–immune signaling: dysbiotic metabolites and inflammatory mediators can activate enteric/immune pathways, influencing diarrhea vs constipation patterns, nausea, and appetite changes, which further destabilize the microbiome.
innerbuddies gut microbiome testing

Uitleg van de mechanismen

In SIBO, the small intestine loses its normal “low-bacteria” protection, allowing colon-like microbes to migrate upward and multiply. When stomach acid is reduced and antimicrobial defenses (including peptide-mediated activity and bile/enzymatic barriers) don’t adequately suppress organisms, bacteria can survive the upper gut and establish themselves where they shouldn’t. This shift in microbial distribution changes what and how microbes ferment, increasing gas production from carbohydrates that escape complete digestion—often leading to post-meal bloating, distension, and cramping.

A key driver is impaired clearance from the small intestine, commonly through disrupted gut motility and a weakened migrating motor complex (MMC). If transit is slow or the MMC does not reliably sweep bacteria out between meals, luminal organisms remain longer in the small bowel and are more likely to form biofilms. Over time, the microbial community can become more fermentation-oriented, producing excess hydrogen and/or methane byproducts. Because meals provide fresh substrates (and can modify bile acid signaling), microbial activity often spikes after eating, intensifying symptoms in a predictable postprandial pattern.

These microbial outputs can further destabilize the gut environment by irritating the mucosa and altering neuromuscular function. Fermentation byproducts can increase the osmotic and inflammatory burden in the lumen, contributing to visceral hypersensitivity and ongoing motility changes that perpetuate symptoms. Chronic dysbiosis may also impair digestion and nutrient absorption, which can explain weight loss or nutrient deficiencies such as possible vitamin B12 issues in some people. As dysbiotic metabolites influence gut–brain–immune signaling, immune activation and altered enteric signaling can shift symptom patterns toward diarrhea or constipation, while also affecting appetite and nausea—creating a feedback loop that sustains SIBO risk unless underlying drivers of dysbiosis are addressed.

innerbuddies gut microbiome testing

Microbiële patronen – samenvatting

In SIBO, the hallmark microbial pattern is a loss of the small intestine’s normal “low-bacteria” environment, allowing colon-associated organisms to migrate upward and establish higher-than-expected populations in the small bowel. This shift is often driven by reduced antimicrobial defenses (such as lower stomach acid) and by breakdowns in the gut’s ability to clear luminal contents between meals. As a result, the microbial community becomes less adapted to remaining sparse and more capable of persisting in the small intestine, where nutrient availability after meals can rapidly amplify their growth.

As the overgrown community takes hold, the dominant functional pattern tends to become more fermentative, increasing gas production—commonly hydrogen and sometimes methane—especially when carbohydrates are incompletely digested or reach the small intestine. After eating, microbial activity often rises because meals supply fresh substrates and can influence bile acid signaling, creating a predictable postprandial spike in fermentation. Over time, these microbes may form more durable biofilm-like communities and further reinforce an environment that favors persistent overgrowth rather than clearance.

The fermentation byproducts and metabolite profiles associated with these altered communities can destabilize the intestinal milieu, promoting symptoms through effects on mucosal irritation, immune activation, and neuromuscular regulation. This microbial–host interaction can contribute to impaired digestion and nutrient absorption, which may relate to nutrient deficiencies in some individuals (including potential vitamin B12 issues), and can shift bowel habits toward diarrhea or constipation depending on the prevailing metabolic and inflammatory effects. Without addressing underlying drivers such as slow transit, MMC disruption, or structural/acid-related factors, these dysbiotic patterns can become self-sustaining and increase recurrence risk.

innerbuddies gut microbiome testing

Lage niveaus van gunstige taxa

  • Streptococcus (including early gut colonizers)
  • Lactobacillus (and related lactic-acid bacteria)
  • Bifidobacterium
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale group
  • Akkermansia muciniphila
  • Bacteroides fragilis group
innerbuddies gut microbiome testing

Verhoogde / oververtegenwoordigde taxa

  • Lactose-fermenting Enterobacteriaceae (e.g., Escherichia/Shigella)
  • Streptococcus (oral-type small-intestinal overgrowth strains)
  • Enterococcus
  • Bacteroides (colon-associated Bacteroides spp., post-migration)
  • Ruminococcus gnavus group
  • Methanogenic archaea (e.g., Methanobrevibacter smithii)
innerbuddies gut microbiome testing

Betrokken functionele pathways

  • Carbohydrate fermentation to hydrogen and short-chain fatty acids (e.g., lactate and acetate production)
  • Methanogenesis (archaeal pathways, including hydrogen utilization by Methanobrevibacter spp.)
  • Lactose and other disaccharide utilization/incomplete digestion leading to fermentation substrates
  • Biofilm formation and persistence mechanisms in the small intestine (colonization and adherence programs)
  • Bile acid deconjugation and bile acid metabolism alterations that change antimicrobial signaling and microbial survival
  • Proteolytic fermentation/amino-acid catabolism (including ammonia and other irritant metabolites that can affect gut motility)
  • Disruption of intestinal barrier function and mucosal inflammation signaling (microbe-associated metabolite-driven immune activation)
  • Reduced antimicrobial defense function linked to altered small-bowel ecology (e.g., acid-/stress-response related survival pathways)
innerbuddies gut microbiome testing

Opmerking over diversiteit

In SIBO, the key diversity shift is less about a simple “more or less bacteria” change and more about community misplacement: organisms that are normally concentrated in the colon gain access to the small intestine, where the microbiome is typically sparse and more specialized. This often corresponds with reduced ecological stability in the small bowel, including a loss of the normal low-biomass, low-fermentative communities. As overgrowth takes hold, the community composition becomes more dominated by colon-associated taxa that are well adapted to utilize available nutrients in that region.

Functionally, this altered community structure tends to reduce normal diversity of ecological niches in the small intestine and replace them with microbes that can persist and metabolize substrates efficiently, especially after meals. The result is a more fermentation-prone microbial profile, with community members that thrive on incompletely digested carbohydrates and produce higher levels of hydrogen and, in some individuals, methane. This can create a feedback loop where postprandial substrate availability repeatedly supports the same overrepresented populations, further crowding out less compatible microbes.

Over time, the dysbiotic small-intestinal ecosystem may become more resilient due to biofilm-like behavior or other mechanisms that protect resident communities from clearance. That persistence can further narrow effective functional diversity—shifting the microbiome’s output toward gas- and metabolite-driven patterns that irritate the intestinal lining and disrupt motility. Unless underlying drivers (e.g., impaired migrating motor complex activity, low gastric acidity, or slow transit) are addressed, these reduced-stability diversity patterns can make recurrence more likely.


Waarom generieke oplossingen falen

  • Probleem met generieke oplossingen

    Generic SIBO treatments often fail because they target “bacteria” in a vacuum rather than the specific problem of a high-bacteria environment in the small intestine. The disorder is usually driven by upstream protective breakdowns—insufficient stomach acid and, more importantly, impaired clearance between meals (e.g., migrating motor complex disruption, slow transit, or motility disorders). When those root mechanisms remain unchanged, any improvement from a broad antimicrobial or dietary change can be temporary, allowing colon-associated organisms to repopulate the small bowel and re-establish fermentation within days to weeks.

    In addition, generic diets commonly emphasize broad carbohydrate restriction without accounting for how SIBO fermentation patterns actually respond to meals. Many people feel worse after eating because the small intestine suddenly receives fermentable substrates, creating a predictable postprandial spike in hydrogen and/or methane. A one-size-fits-all approach can either undersupply nutrients (worsening malabsorption and symptoms) or fail to meaningfully reduce the specific substrate load that the overgrowth is using, leaving gas production and mucosal irritation essentially intact.

    Finally, generic “probiotics for everyone” strategies often miss the fact that SIBO is defined by wrong-location microbial dominance and biofilm-like persistence. Introducing organisms indiscriminately may not restore the small-intestinal low-density state and can sometimes increase fermentative activity or interact with underlying motility and bile-acid signaling issues. Without a plan that addresses antimicrobial/clearance timing, root drivers (motility/acid/structural factors), and the functional fermentation outputs, SIBO tends to recur and symptoms remain linked to meals rather than improving steadily.

  • Veelvoorkomende fouten

    • Treating SIBO as a generic “bacteria problem” without addressing the root cause of a high-bacteria small intestine (e.g., low stomach acid and especially impaired MMC/migrating motor complex function, slow transit, or motility disorders).
    • Using broad, non-targeted antimicrobial approaches without a clearance strategy; this allows colon-associated organisms to repopulate the small bowel and symptoms to recur within days to weeks.
    • Over-relying on one-size-fits-all carbohydrate restriction that doesn’t match SIBO meal-driven fermentation dynamics, causing predictable postprandial gas/fermentation spikes and/or worsening nutrient intake when digestion is already impaired.
    • Not aligning diet and treatment timing with post-meal microbial activity (e.g., failing to account for how meals rapidly change substrate availability to overgrowth, triggering symptom flares).
    • Prescribing “probiotics for everyone” without considering wrong-location dominance and biofilm-like persistence; indiscriminate organisms may fail to restore low small-intestine density and can sometimes increase fermentative activity.
    • Ignoring functional/fermentation outputs (hydrogen/methane production, bile-acid-related effects, mucosal irritation) and focusing only on composition, so symptoms remain linked to meals.
    • Failing to screen for or manage contributing structural or acid-related drivers (e.g., anatomic issues, PPI overuse, gastric dysfunction), leading to incomplete resolution and recurrence.
    • Assuming symptom improvement means the underlying overgrowth environment is corrected; without validating clearance and ongoing motility/antimicrobial defenses, relapse risk remains high.

Wat te doen

  • Algemene ondersteuningsstrategieën

    Supporting small intestinal bacterial overgrowth (SIBO) typically starts with restoring the conditions that normally keep bacterial density low in the small intestine. When stomach acid, small-bowel motility (the migrating motor complex), or transit timing are impaired, bacteria that would normally reside in the colon can proliferate where they don’t belong. Addressing these upstream factors helps reduce recurrence risk and makes antimicrobial or microbiome-targeting approaches more effective. Over time, improving gut motility and maintaining a healthy overall microbial balance can help normalize fermentation patterns, which is important because excess bacterial activity in the small intestine can drive hydrogen and/or methane production from carbohydrates that are not fully digested.

    Diet is often used as a practical lever to limit fuel for fermentation while the gut is being rebalanced. Many people notice symptoms worsen after meals, so temporary dietary strategies may focus on reducing fermentable, rapidly available carbohydrates that can escape digestion and feed overgrowth, which can lessen bloating, distension, gas, and cramping. At the same time, the goal is not long-term food restriction, but rather a guided, symptom-sensitive approach that supports tolerance and gradually broadens variety once symptoms improve. Because malabsorption and nutrient depletion can occur in some individuals, attention to adequate protein, micronutrients, and hydration is also part of general support.

    Long-term improvement generally involves a combined, gut-ecosystem view: targeting overgrowth, reducing inflammatory strain, and supporting re-stabilization of the microbiome. Some patients benefit from interventions that help rebalance microbial communities after the overgrowth is controlled, along with lifestyle measures that support circadian rhythm, bowel regularity, and gut–brain signaling. Since underlying causes—such as slow transit, motility disorders, prior gut surgery, or acid-suppressing medications—can perpetuate SIBO, identifying and correcting these drivers alongside gut-focused strategies is key for more durable outcomes.

  • Lifestyleadviezen

    • Follow a clinician-guided, temporary low-FODMAP or carbohydrate-restricted eating plan to reduce fermentable substrates that feed SIBO-related gas production.
    • Eat smaller, more regular meals and avoid large, high-carbohydrate meals that commonly worsen post-meal bloating and distension.
    • Support intestinal motility with daily movement (e.g., walking after meals) and consistent exercise; avoid prolonged sedentary periods.
    • Address potential risk factors for overgrowth by minimizing unnecessary acid suppression (e.g., PPIs) only under medical guidance, and ensure adequate hydration.
    • Establish regular bowel habits and consider a fiber approach that fits your symptoms (e.g., gradual, clinician-approved adjustments) rather than abrupt high-fiber increases.
    • Limit alcohol and avoid smoking, as both can worsen gut barrier function and dysbiosis.
    • Use stress-reduction practices (e.g., mindfulness, CBT tools, yoga) because gut–brain signaling can affect motility and symptom severity.

  • Voedingsaanbevelingen

    • Use a temporary low-FODMAP approach (especially limiting lactose, fructans, and certain sugar alcohols) to reduce fermentation-driven gas and bloating; reintroduce foods gradually once symptoms improve to avoid unnecessary long-term restriction.
    • Limit high-labile fermentable carbs during flares (e.g., onions, garlic, wheat-based products, beans/lentils, apples/pears, and “keto”/sugar-free polyols like sorbitol, xylitol, maltitol) and prioritize lower-FODMAP alternatives (e.g., rice, oats, potatoes, carrots, spinach, zucchini).
    • Choose carbohydrates you can tolerate in smaller portions (e.g., well-cooked starches) because larger meals can increase substrate availability in the small intestine and amplify gas production after eating.
    • Emphasize adequate protein and generally lower-fermenting foods (eggs, fish, poultry, tofu/tempeh if tolerated, firm cheeses in lactose-intolerant individuals as tolerated) to support digestion and reduce the overall fermentable load.
    • Be cautious with fiber supplements and “prebiotic” products initially (inulin/chicory root, FOS, resistant starch) as they can worsen symptoms by feeding overgrown/fermentative microbes; if adding fiber, start slowly with low-FODMAP options.
    • Avoid or reduce alcohol and excess added sugars, which can worsen dysbiosis and may increase fermentable substrate available to microbes.
    • Consider a targeted, food-first approach to meal timing and distribution (smaller, evenly spaced meals) to reduce post-meal distension/irritation and support motility-related symptom control alongside medical management.

  • Overwegingen bij supplementen

    For small intestinal bacterial overgrowth (SIBO), supplement strategies generally aim to reduce abnormal bacterial activity in the small intestine and help restore the conditions that normally keep the small-bowel environment low in bacterial density. Because symptom flares often follow meals—when undigested carbohydrates reach the small intestine—supporting carbohydrate digestion and reducing fermentable substrate availability can be helpful alongside targeted antimicrobials. Options commonly considered include antimicrobial botanicals (e.g., oregano oil, berberine, neem, or other standardized plant extracts) and, in some cases, agents designed to specifically address hydrogen- and methane-producing pathways. The best choice depends on symptom pattern and whether hydrogen- or methane-predominant physiology is suspected.

    Because the drivers of SIBO recurrence often include impaired “housekeeping” motility and reduced gastric acidity, some supplements may be used as functional support to promote regular intestinal clearance and improve upstream digestive readiness. This can include gut-motility–supporting nutrients/compounds (used thoughtfully and individualized to tolerability), as well as betaine HCl or digestive enzymes in select people who have evidence of low stomach acid—while avoiding acidification if it worsens reflux or gastritis. Improving digestion efficiency may also lower the amount of carbohydrate reaching the small intestine for fermentation, which can reduce bloating, gas, and cramping.

    Finally, after or alongside antimicrobial approaches, many supplement plans incorporate microbiome-supportive elements to help re-establish a healthier microbial balance and reduce ongoing fermentation-related symptoms. Probiotic use in SIBO is nuanced: while certain strains may support gut barrier function and motility-related signaling, the wrong strain mix or dose can sometimes worsen gas or distension in sensitive individuals. Other supportive nutrients—such as zinc, magnesium, and B-vitamin support (including B12 if deficiency is suspected)—may be relevant when malabsorption, diarrhea/constipation cycles, or dietary restriction have contributed to nutrient gaps. Given the recurrence risk tied to underlying motility or structural issues, supplementation is typically most effective when paired with addressing those root causes.

  • Hertesten / monitoring notitie

    With SIBO, retesting is typically recommended after an initial treatment cycle to confirm whether bacterial levels and fermentation activity have normalized. Because symptoms can overlap with other causes of bloating and altered bowel habits, follow-up testing helps distinguish between persistent overgrowth, relapse, or an alternative diagnosis (such as IBS or carbohydrate malabsorption). Many clinicians time retesting to allow the gut environment to stabilize after therapy, rather than testing immediately at the end of antibiotics or antimicrobial regimens.

    Retesting should also account for the specific testing method used initially, since breath testing (hydrogen, methane, and sometimes hydrogen sulfide) reflects gas production patterns rather than direct bacterial counts. If your first test showed hydrogen and/or methane elevation, a repeat test can be used to track response and guide next steps—especially if symptoms persist or return quickly. If initial symptoms were driven by meal-related gas, retesting can be particularly useful when the pattern suggests ongoing fermentation in the small intestine.

    Just as important as “whether” to retest is “why” SIBO may be recurring. When the underlying drivers—reduced stomach acid, impaired migrating motor complex/slow transit, motility disorders, or structural changes—haven’t been addressed, relapse risk remains high. For that reason, retesting is often recommended alongside a review of those contributing factors and any longer-term maintenance plan, so that microbiome restoration is supported by improved small-intestinal clearance and appropriate dietary and lifestyle adjustments.

Het belang van darmmicrobioomtesten

  • Waarom testen belangrijk is

    Gut microbiome testing matters in suspected SIBO because it helps clarify whether symptoms reflect true overgrowth and dysbiosis in the small intestine, versus other causes with overlapping signs like IBS, intolerance, celiac disease, or medication-related malabsorption. Since SIBO involves an abnormal shift in where bacteria live and how they ferment, profiling microbial patterns can provide useful context about whether the gut environment is more likely to support methane- or hydrogen-producing communities that intensify gas and bloating after meals.

    Testing can also help identify underlying drivers that weaken the gut’s “braking systems” for microbial migration—such as impaired motility, altered bile acid handling, or reduced stomach acidity—because these factors shape the overall ecosystem, not just one organism. By understanding an individual’s baseline microbiome and related functional signatures (for example, fermentation potential and dominant metabolic pathways), clinicians can better tailor next steps rather than relying on trial-and-error approaches.

    Finally, gut microbiome results can guide prevention and reduce recurrence risk by informing a longer-term strategy to restore balance after targeted treatment. Because SIBO often returns when root conditions persist, testing can support monitoring of recovery—helping confirm whether microbial patterns are trending toward a healthier distribution and whether symptoms like bloating, distension, diarrhea, or constipation align with improved ecosystem stability.

  • Hoe InnerBuddies helpt

    InnerBuddies can help in suspected SIBO by giving a more personalized snapshot of gut microbiome composition and functional activity, which is closely tied to where bacteria thrive and how they ferment nutrients. Because SIBO involves an abnormal shift in bacterial density and metabolic behavior in the small intestine, the test can provide context about whether an ecosystem is trending toward hydrogen- and/or methane-associated fermentation patterns that commonly drive post-meal bloating, distension, gas, and cramping.

    Beyond identifying microbial imbalance, InnerBuddies can support clinicians in interpreting likely “drivers” that weaken the gut’s normal protective mechanisms, such as disrupted motility, altered bile acid handling, and reduced gastric acidity. Understanding these ecosystem-level factors matters because SIBO frequently recurs when underlying conditions remain. Test insights can help tailor next steps rather than relying solely on trial-and-error, by aligning dietary strategies and targeted interventions with the microbiome and metabolic signatures that appear most relevant.

    Finally, InnerBuddies can be useful for monitoring recovery and recurrence risk. After treatment and lifestyle changes, re-testing may show whether microbial patterns are moving toward a healthier, more stable balance—potentially correlating with symptom improvement (for example, fewer symptoms after meals, less bloating and flatulence, and improved stool consistency). This makes the testing approach not only diagnostic-supportive, but also practical for tracking whether the gut ecosystem is stabilizing over time.

Medische bewijs

  • Wetenschappelijk bewijsniveau

    2 [weak to emerging evidence for association; limited causal/intervention/clinical-utility support]

  • Klinische relevantie

    Overall confidence (GRADE-inspired): Low (with very limited high-quality causal/interventional evidence). Mechanistically, microbiome composition, bile acid metabolism, intestinal motility, mucosal barrier function, and immune signaling could plausibly influence bacterial colonization of the small intestine (and vice versa). Still, in humans, the strongest relevance would require small-intestinal (mucosal/aspirate) microbiome profiling and careful phenotyping of SIBO, which is often not done.

    Clinical relevance: At present, gut microbiome profiling (especially stool-based microbiome) is not validated for routine prevention, diagnosis, treatment selection, or monitoring of SIBO. Current clinical practice relies on symptoms and breath testing, and treatment (commonly antibiotics such as rifaximin, and addressing underlying causes like motility disorders/strictures) is not guided by microbiome biomarkers. While future work could identify microbial signatures linked to SIBO subtypes and recurrence, the field remains methodologically heterogeneous and lacks external validation, prospective predictive designs using clinically meaningful endpoints, and microbiome-targeted RCTs with durable outcomes.


Hieronder vindt u een overzicht van de belangrijkste medische publicaties die verband houden met deze specifieke aandoening.

Title Journal Year Link
A systematic review and meta-analysis of the microbiota in small intestinal bacterial overgrowth Gastroenterology Research and Practice 2021 —
Small intestinal bacterial overgrowth: diagnosis and management Therapeutic Advances in Gastroenterology 2019 —
Microbial signatures in small intestinal bacterial overgrowth detected by 16S rRNA gene sequencing of duodenal aspirates Journal of Clinical Gastroenterology 2014 —
Microbiota characteristics of patients with small intestinal bacterial overgrowth and correlation with clinical parameters Gut Microbes 2013 —
Gut microbiota in small intestinal bacterial overgrowth and after treatment with rifaximin: a longitudinal study Alimentary Pharmacology & Therapeutics 2010 —

Veelgestelde vragen

    Wat is SIBO en hoe ontstaat het?
    SIBO is wanneer te veel bacteriën in de dunne darm groeien, vaak omdat beschermende factoren zoals maagzuur of regelmatige darmmotiliteit verzwakken, waardoor bacteriën kunnen vermenigvuldigen.
    Wat zijn de meest voorkomende symptomen van SIBO?
    Een opgeblazen gevoel en buikuitzetting, overmatig gas, buikpijn na de maaltijden, diarree of zachte ontlasting, obstipatie of onregelmatige stoelgang, misselijkheid en soms malabsorptie.
    Hoe vaak komt SIBO voor in de algemene bevolking en bij risicogroepen?
    Bij volwassenen ligt de prevalentie meestal in het lage percentage (ongeveer 4–7%), met hogere cijfers bij factoren die de darmtransit vertragen.
    Welke rol speelt de darmmicrobiota bij SIBO?
    De microbiota verschuift naar meer fermenterende bacteriën die na de maaltijd gas produceren, wat bijdraagt aan symptomen en mogelijk ontsteking.
    Wat zijn waterstof- en methaanproducerende SIBO en waarom is dat belangrijk?
    Soms produceren overgroeiingen vooral waterstof, andere keren methaan; dit kan symptomen en testpatronen beïnvloeden en richting geven aan interpretatie onder begeleiding.
    Hoe wordt SIBO gediagnosticeerd?
    De diagnose is meestal gebaseerd op symptomen en risicofactoren, waarbij ademtesten vaak worden gebruikt om de diagnose te ondersteunen en andere oorzaken uit te sluiten.
    Wat vertelt microbiomen testen ons over SIBO?
    Ze kunnen de balans van bacteriën en fermentatiepatronen laten zien, wat helpt begrijpen of de omgeving vatbaar is voor waterstof- of methaanproductie.
    Welke factoren vergroten het risico op terugkeer van SIBO?
    Aanhoudende langzame darmtransit, motoriekstoornissen, structurele veranderingen of zuuronderdrukking kunnen het terugkeren vergroten.
    Wat moet een arts overwegen bij de behandeling van vermoed SIBO?
    Uitvoering gericht op vermindering van de overgroei en aanpak van onderliggende oorzaken zoals motiliteit en zure omstandigheden, met monitoring van symptomen; plannen zijn individueel.
    Kan SIBO leiden tot tekorten aan voedingsstoffen zoals vitamine B12?
    Ja, bij persistente malabsorptie kan dit leiden tot tekorten zoals B12, hoewel niet iedereen dit ervaart.
    Hoe kun je symptomen verminderen of de darmgezondheid ondersteunen?
    Werk samen met een zorgverlener aan de onderliggende oorzaken, blijf goed gehydrateerd en volg betrouwbare voedingsrichtlijnen; vermijd zelfdiagnose.
    Hoe helpen InnerBuddies-tests bij vermoed SIBO?
    InnerBuddies biedt een momentopname van het microbi room en functionele signalen om vermoed SIBO te contextualiseren en samen met de arts de volgende stappen te bepalen.

    Luister naar onze tevreden klanten!

    • "Ik wil je graag laten weten hoe enthousiast ik ben. We waren al zo'n twee maanden op dieet (mijn man eet mee). We voelden ons er beter door, maar hoeveel beter merkte je eigenlijk pas tijdens de kerstvakantie, toen we hadden een groot kerstpakket gekregen en hielden ons al een tijdje niet meer aan het dieet. Nou dat gaf wel weer motivatie, want wat een verschil in maag-darmklachten maar ook energie bij ons allebei!”

      - Manon, 29 jaar -

    • "Super hulp!!! Ik was al een eind op weg, maar nu weet ik zeker wat ik wel en niet moet eten, drinken. Ik heb al zo lang last van maag en darmen, hoop dat ik er nu vanaf kan komen ."

      - Petra, 68 jaar -

    • "Ik heb uw uitgebreide rapport en advies gelezen. Hartelijk dank daarvoor en zeer informatief. Op deze manier gepresenteerd kan ik er zeker mee verder. Voorlopig dus geen nieuwe vragen. Ik neem uw suggesties graag ter harte. En veel succes met uw belangrijke werk."

      - Dirk, 73 jaar -